MedDataX Logo

Pharmacovigilance and Patient Compliance in Hypertensive Patients

NCT ID: NCT02200575

Last Updated: 2014-07-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10333 participants

Study Classification

OBSERVATIONAL

Study Start Date

1999-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to confirm the safety profile of telmisartan (benefit-risk ratio) under normal conditions of use after market launch and to supplement the present data on the safety of telmisartan. Furthermore to assess effectiveness of a single dose of telmisartan per day to control blood pressure for 24 hours, especially during the last few hours of the dosage interval. Additionally to evaluate compliance with treatment, as an indirect measurement, and to confirm the efficacy and possible risks associated with treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients

NCT02242851

Hypertension
COMPLETED

Micardis®. Observational Study in Patients With Essential Hypertension

NCT02200094

Hypertension
COMPLETED

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

NCT02176850

Hypertension
COMPLETED

Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

NCT02238262

Hypertension
COMPLETED

Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide

NCT02248129

Hypertension
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with non-secondary, essential hypertension

Telmisartan

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Micardis®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients of either sex over the age of 18 years suffering from non-secondary essential hypertension with values of at least 90 mmHg (diastolic) and 140 mmHg (systolic)

Exclusion Criteria

\- corresponding to the contraindications listed in the summary of product characteristics of the drug
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.359

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Telmisartan in Mild to Moderate Hypertensive Patients
NCT02260089 COMPLETED PHASE4
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
NCT00638911 COMPLETED
The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension
NCT00471003 COMPLETED
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
NCT02242318 COMPLETED PHASE4
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
NCT00909038 COMPLETED
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
NCT00168779 COMPLETED PHASE4
Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure
NCT02242331 COMPLETED
Telmisartan Tab Hypertension
NCT00890084 COMPLETED
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland
NCT01211171 COMPLETED
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
NCT00219154 COMPLETED PHASE3
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
NCT00422461 COMPLETED PHASE2
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia
NCT01217879 COMPLETED
Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
NCT00034840 COMPLETED PHASE4
Antihypertensive Medications and the Risk of Sepsis
NCT02248896 COMPLETED
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
NCT00362115 COMPLETED PHASE2
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
NCT00219050 COMPLETED PHASE3
A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
NCT00240448 COMPLETED PHASE4
Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension
NCT00759551 COMPLETED PHASE2
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
NCT00219063 COMPLETED PHASE3
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
NCT00927537 COMPLETED
Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension
NCT00523744 COMPLETED PHASE3
Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis
NCT02178306 COMPLETED PHASE4
Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers
NCT02262780 COMPLETED PHASE1
Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.
NCT00750113 COMPLETED PHASE4
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
NCT00260923 COMPLETED PHASE3